Lilly, Alkermes release data showing Exubera oral insulin as good as injected

09/13/2005 | Forbes

In response to an FDA advisory panel's concerns about their inhaled insulin drug, Exubera, Eli Lilly and Alkermes disclosed data showing their drug worked as well as the usual injected form of insulin. The firms also said they have begun enrollment for a Phase III trial aimed at assessing the safety and efficacy of the drug.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI